{"References": [{"title": "FGFR2 fusions define a distinct molecular subset in intrahepatic cholangiocarcinoma", "authors": "Nowell SA, Klimowicz AC, Cleary JL, Zhang Q, Wang Y, Zhang J, Maitra A, Hruban RH, Wolfgang CL, Anders RA", "journal": "Oncotarget", "year": "2015", "volumes": "6", "first page": "39448", "last page": "39463", "DOI": "10.18632/oncotarget.5775"}, {"title": "Genomic and transcriptomic features of biliary tract cancers and clinical utility of next-generation sequencing", "authors": "Jiao Y, Pawlik TM, Anders RA, Wolfgang CL, Hruban RH, Maitra A, Schulick RD, Wolfgang CL, Hruban RH, Maitra A", "journal": "Gastroenterology", "year": "2013", "volumes": "144", "first page": "1442", "last page": "1452", "DOI": "10.1053/j.gastro.2013.02.045"}, {"title": "Comprehensive genomic characterization of intrahepatic cholangiocarcinoma reveals frequent IDH1/2 and BAP1 mutations", "authors": "Jiao Y, Pawlik TM, Anders RA, Wolfgang CL, Hruban RH, Maitra A, Schulick RD, Wolfgang CL, Hruban RH, Maitra A", "journal": "Nature Genetics", "year": "2013", "volumes": "45", "first page": "1470", "last page": "1476", "DOI": "10.1038/ng.2818"}, {"title": "Fibroblast growth factor receptor 2 tyrosine kinase inhibitors for the treatment of advanced cholangiocarcinoma with FGFR2 fusion", "authors": "Zhu AX, Meyerhardt JA, Blaszkowsky LS, Abrams TA, Bendell JC, Hollebecque A, Infante JR, Javle MM, Lowery MA, Macarulla T", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36", "first page": "1550", "last page": "1558", "DOI": "10.1200/JCO.2017.76.7585"}, {"title": "Targeting FGFR2 fusions in intrahepatic cholangiocarcinoma", "authors": "Abou-Alfa GK, Javle MM, Lowery MA, Macarulla T, Hollebecque A, Infante JR, Zhu AX, Bendell JC, Blaszkowsky LS, Abrams TA", "journal": "Nature Reviews Gastroenterology & Hepatology", "year": "2018", "volumes": "15", "first page": "557", "last page": "568", "DOI": "10.1038/s41575-018-0039-5"}, {"title": "Efficacy and safety of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study", "authors": "Abou-Alfa GK, Macarulla T, Javle MM, Hollebecque A, Infante JR, Zhu AX, Bendell JC, Blaszkowsky LS, Abrams TA, Lowery MA", "journal": "The Lancet Oncology", "year": "2020", "volumes": "21", "first page": "831", "last page": "842", "DOI": "10.1016/S1470-2045(20)30109-1"}, {"title": "Inhibition of FGFR2 fusion by the selective FGFR inhibitor AZD4547 in cholangiocarcinoma", "authors": "Zhu AX, Blaszkowsky LS, Abrams TA, Bendell JC, Hollebecque A, Infante JR, Javle MM, Lowery MA, Macarulla T, Abou-Alfa GK", "journal": "Clinical Cancer Research", "year": "2017", "volumes": "23", "first page": "5942", "last page": "5950", "DOI": "10.1158/1078-0432.CCR-17-0654"}, {"title": "Preclinical rationale for targeting FGFR2 fusions in cholangiocarcinoma", "authors": "Nowell SA, Klimowicz AC, Cleary JL, Zhang Q, Wang Y, Zhang J, Maitra A, Hruban RH, Wolfgang CL, Anders RA", "journal": "Molecular Cancer Therapeutics", "year": "2015", "volumes": "14", "first page": "2749", "last page": "2759", "DOI": "10.1158/1535-7163.MCT-15-0465"}, {"title": "Mechanisms of acquired resistance to FGFR inhibition in cholangiocarcinoma with FGFR2 fusions", "authors": "Zhang J, Zhang Q, Nowell SA, Klimowicz AC, Cleary JL, Wang Y, Maitra A, Hruban RH, Wolfgang CL, Anders RA", "journal": "Cancer Discovery", "year": "2016", "volumes": "6", "first page": "1370", "last page": "1385", "DOI": "10.1158/2159-8290.CD-16-0445"}, {"title": "Genetic alterations in biliary tract cancers: implications for targeted therapies", "authors": "Jiao Y, Pawlik TM, Anders RA, Wolfgang CL, Hruban RH, Maitra A, Schulick RD, Wolfgang CL, Hruban RH, Maitra A", "journal": "Cancer Discovery", "year": "2013", "volumes": "3", "first page": "1215", "last page": "1227", "DOI": "10.1158/2159-8290.CD-13-0365"}]}